AlphaLife Sciences Joins Johnson & Johnson Innovation – JLABS in Singapore to Accelerate AI-Driven Clinical Research

AlphaLife Sciences is very pleased to announce its residency at Johnson & Johnson Innovation——JLABS ("JLABS") in Singapore. JLABS is the world's largest network of open innovation ecosystems, providing emerging companies with knowledge, expertise, partnerships, and venture capital connections across all areas of healthcare, including pharmaceuticals and medical technology. This milestone highlights the value and potential of AlphaLife Sciences in the field of artificial intelligence for clinical research.

As a new member of JLABS, AlphaLife Sciences reaffirms its commitment to thoroughly accelerating the clinical research process. The company’s AI-assisted medical writing solutions and intelligent EDC and data management solutions have already gained recognition from global multinational pharmaceutical companies, showcasing its strong growth momentum and relentless pursuit of innovation. Ms. Chen Xiao, CEO and co-founder of AlphaLife Sciences, stated, “Being accepted into JLABS is a tremendous honor and an exciting opportunity. We are thrilled to join the ranks of high-impact startups that have benefited from JLABS’ nurturing ecosystem. This collaboration will significantly expedite our mission to deliver better and more efficient solutions, accelerate the clinical research process, and bring better drugs to patients faster.”

AlphaLife Sciences will continue to refine its technology and expand its influence, aiming to transform the clinical research process through the power of generative artificial intelligence, cloud computing, and other cutting-edge technologies. It is the only company in Asia selected by Johnson & Johnson JLABS, Microsoft for Startups Pegasus Program, and Google for Startups.Global LeadingWith the joint support of the incubator, the company is more confident in bringing its groundbreaking technology to those who need it most.